- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Robert J. Motzer, MD | Authors
Articles
Future Use of Novel Combinations for Metastatic RCC Treatment
March 17, 2021
Drs Toni Choueiri and Robert J. Motzer highlight various strategies with novel-based therapies being explored to address limitations surrounding the treatment of metastatic renal cell carcinoma.
Risk Scoring Systems for Metastatic RCC
March 17, 2021
Considerations regarding the value of using the IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) criteria to risk-stratify patients with metastatic renal cell carcinoma as novel therapies become more widely used.
Implications for Treating Metastatic RCC With TKI/I-O Regimens Upfront
March 17, 2021
Recommendations regarding how to use novel combinations such as lenvatinib and everolimus, or lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma.
Metastatic RCC: Frontline TKI/IO Safety Data
March 17, 2021
Treatment-related adverse events to be mindful of when treating patients with metastatic renal cell carcinoma with a TKI/IO regimen, such as lenvatinib and pembrolizumab, in the frontline setting.
The Phase 3 CLEAR Study in Metastatic RCC
March 17, 2021
Robert J. Motzer, MD, of the Memorial Sloan Kettering Cancer Center, discusses the rationale for studying lenvatinib plus pembrolizumab or everolimus for frontline metastatic renal cell carcinoma treatment and reacts to outcomes of the phase 3 CLEAR study as presented at ASCO GU 2021.
Personal Approaches to Frontline Therapy for Metastatic RCC
March 17, 2021
Drs Toni Choueiri and Robert J. Motzer discuss factors that impact their decisions for treatment of metastatic renal cell carcinoma in the first-line setting and highlight their go-to regimens.
Frontline Combination Approaches for Metastatic RCC
March 17, 2021
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, comments on the impact of emerging data presented on newer, novel combination therapies as upfront treatment for patients with metastatic renal cell carcinoma.
Refining Combination Strategies in Metastatic RCC
March 17, 2021
Drs Toni Choueiri and Robert J. Motzer reflect on recent data supporting the use of TKI/I-O combination regimens for frontline treatment of metastatic renal cell carcinoma.
Robert J. Motzer, MD, on Research Areas of Focus in Renal Cell Carcinoma
March 09, 2021
The medical oncologist at Memorial Sloan Kettering Cancer Center discussed areas of research in renal cell carcinoma that he thinks should be further explored.
Robert J. Motzer, MD, on the Possible Impact of a Phase 3 Trial for Advanced ccRCC
March 07, 2021
The medical oncologist at Memorial Sloan Kettering Cancer Center explained how this trial of MK-6482 plus lenvatinib versus cabozantinib in patients with advanced clear cell renal cell carcinoma could possibly improve the standard of care in this setting.